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Summary. Hormone replacement therapy (HRT) increases
the risk of venous thrombosis. We investigated whether this
risk is affected by carriership of hereditary prothrombotic
abnormalities. Therefore, we determined the two most
common prothrombotic mutations, factor V Leiden and
prothrombin 20210A in women who participated in a
case–control study on venous thrombosis. Relative risks
were expressed as odds ratios (OR) with 95% confidence
intervals (CI95). Among 77 women aged 45–64 years with
a first venous thrombosis, 51% were receiving HRT at the
time of thrombosis, compared with 24% of control women
(OR ¼ 3Æ3, CI95 1Æ8–5Æ8). Among the patients, 23% had a
prothrombotic defect, versus 7% among the control women
(OR ¼ 3Æ8, CI95 1Æ7–8Æ5). Women who had factor V Leiden
and used HRT had a 15-fold increased risk (OR ¼ 15Æ5,
CI95 3Æ1–77), which exceeded the expected joint odds ratio
of 6Æ1 (under an additive model). We conclude that the
thrombotic risk of HRT may particularly affect women with
prothrombotic mutations. Efforts to avoid HRT in women
with increased risk of thrombosis are advisable.
Keywords: venous thrombosis, oestrogens, hormone
replacement therapy, factor V Leiden, prothrombin
20210A.
Several recent studies have demonstrated that the use of
hormone replacement therapy (HRT) is associated with an
increased risk of venous thrombosis, i.e. deep-vein throm-
bosis and pulmonary embolism (Daly et al, 1996; Grodstein
et al, 1996; Jick et al, 1996; Grady et al, 2000). The reports
pointed to a two- to fourfold increased risk, which is not
very different from the relative risk conferred by oral
contraceptives (Vessey & Doll, 1968; Stadel, 1981). This
was surprising given the low oestrogen and progestogen
doses in HRT. As the risk of thrombosis, in absolute terms, is
highly dependent on age, these data imply that HRT might
lead to a considerable number of excess cases of deep-vein
thrombosis among post-menopausal women.
To prevent thrombosis as a result of the use of HRT, it is
necessary to identify women at increased risk. Previously,
we have demonstrated a synergistic effect between the use
of oral contraceptives and the most common prothrombotic
defect, factor V Leiden (Vandenbroucke et al, 1994).
Therefore, we hypothesized that women with hereditary
thrombophilia would be at high risk of thrombosis when
using HRT.
We reinvestigated participants in the Oxford hospital-
based case–control study (Daly et al, 1996) of HRT and the
occurrence of venous thrombosis for the presence of
prothrombotic mutations, which we limited to the two
most prevalent abnormalities, factor V Leiden and
prothrombin 20210A, each of which is found in several
per cent of the general Caucasian population (Rees et al,
1995; Rosendaal et al, 1998). We have reported previously
on prothrombotic phenotypes in this group (Lowe et al,
2000).
PATIENTS AND METHODS
The original case–control study included 103 women aged
45–64 years admitted to hospital between April 1990 and
December 1994 in the Oxford Regional Health Authority
area, with a main diagnosis of a first episode of deep-vein
thrombosis or pulmonary embolism (Daly et al, 1996). For
comparison, control women were recruited from women
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admitted to hospital for diagnoses unrelated to thrombosis
and HRT. Up to two control women were chosen per case,
matched by 5-year age group, district of admission and date
of hospitalization. Women with a history of stroke, myo-
cardial infarction, malignancies or who had been pregnant,
had undergone surgery or had been immobilized in the
6 weeks before admission were excluded from the case and
control groups. Results have been published previously
(Daly et al, 1996).
For the follow-up study in 1995–96 (Lowe et al, 2000),
all surviving women were invited to take part in a study of
thrombotic phenotypes and genotypes. The study was
approved by local research ethics committees. Venous
blood was obtained from the antecubital vein and antico-
agulated with EDTA. DNA was extracted by salting out
procedures. DNA analysis for factor V Leiden (factor V
G1691A) and prothrombin mutation (G20210A) were
performed by standard polymerase chain reaction (PCR)
procedures.
We calculated the relative risk associated with HRT and
with carriership of a prothrombotic mutation by exposure
odds ratios. These indicate the risk of thrombosis in those
with the risk factor relative to those without the risk factor.
Ninety-five per cent confidence intervals (CI95) were
estimated according to the method of Woolf (1955) or
derived from the logistic regression model. When numbers
were small, exact confidence intervals were computed
(Mehta, 1994) using epi info 6 [Centers for Disease Control
(CDC), Atlanta, GA, USA]. The original matching is
accounted for in our analyses by adjustment for age and
district of admission. In some analyses, we grouped factor V
Leiden and prothrombin 20210A carriers together. Where
numbers allowed, we presented separate risk estimates for
both genetic variants. The effect of the combination of
prothrombotic mutations was investigated by comparing
those with either risk factor and those with both risk factors
with those with neither.
RESULTS
DNA was obtained from 77 of the 80 eligible consenting
women with venous thrombosis and 163 of the 171 eligible
consenting control women. Their general characteristics are
shown in Table I.
Among the patients, 51% used HRT at the time of the
thrombosis, compared with 24% of control women, which
indicated a more than threefold increased risk (OR ¼ 3Æ3,
CI95 1Æ8–5Æ8). A prothrombotic mutation (factor V Leiden
or prothrombin 20210A) was present in 23% of women
with thrombosis (all heterozygous) versus 7% among
controls (all heterozygous), with a nearly fourfold
increased risk (OR ¼ 3Æ8, CI95 1Æ7–8Æ5). Adjustment for
the stratification factors, age and area of admission, did
not affect these risk estimates. Factor V Leiden was
associated with a fourfold increased risk (OR ¼ 4Æ0, CI95
1Æ6–10Æ2) and prothrombin 20210A with a twofold
increased risk (OR ¼ 2Æ2, CI95 0Æ2–30Æ3). Of 18 throm-
bosis cases with a prothrombotic mutation, eight were
hormone users at the time of thrombosis. Of these eight
women, five (62%) were in their first year of hormone use,
compared with 32% of all cases using HRT (and 23% of
controls) (Daly et al, 1996).
Subsequently, we investigated the joint effect of pro-
thrombotic mutations and HRT on the risk of venous
thrombosis. Whereas HRT and prothrombotic mutations
separately each increased thrombotic risk about fourfold,
the combination led to an 11-fold increased risk (OR ¼ 11,
CI95 2Æ7–44), which exceeded the expected odds ratio of 7Æ1
if the risks had been additive. Only four women carried the
prothrombin variant, none of whom also used HRT. Given
this low number of carriers, separate risk estimates for this
variant were not meaningful. Table II shows the separate
and joint effects of factor V Leiden and HRT. The combi-
nation of factor V Leiden and hormone treatment increased
the risk of thrombosis 15-fold (OR ¼ 15Æ5, CI95 3Æ1–76Æ7),
clearly exceeding the sum of the separate effects of the two
risk factors (expected joint odds ratio 6Æ1).
DISCUSSION
This reinvestigation of participants in a case–control study
of idiopathic venous thrombosis demonstrated that HRT
and prothrombotic mutations (factor V Leiden, prothrombin
20210A) increase the risk of venous thrombosis in women
aged 45–64 years.
Table I. General characteristics.
Patients
(n ¼ 77)
Controls
(n ¼ 163)
Mean age, years (range) 54 (45–64) 54 (45–64)
Oral anticoagulant therapy (%) 11* (14) 0 (0)
HRT
At thrombosis  (%) 39 (51) 39 (24)
At venepuncture (%) 18 (23) 52 (32)
Factor V Leiden
GG (%) 61 (79) 153 (94)
AG (%) 16 (21) 10 (6)
Prothrombin 20210
GG (%) 75 (97) 161 (99)
AG (%) 2 (3) 2 (1)
*These patients were excluded from previous analyses of hae-
mostatic factors (Lowe et al, 2000).
 Or at a similar index date for the controls.
Table II. Factor V Leiden and HRT.
Factor V Leiden HRT Patients Controls OR CI95
– – 30 116 1
+ – 8 8 3Æ9 1Æ3–11Æ2
– + 31 37 3Æ2 1Æ7–6Æ0
+ + 8 2 15Æ5 3Æ1–76Æ7
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The highest risk of thrombosis was found in women who
used HRT and carried the factor V Leiden mutation (15-
fold). The increased risk of venous thrombosis in HRT users
who are carriers of the factor V Leiden mutation is
consistent with our recent report of an increased risk in
HRT users with activated protein C (APC) resistance, the
thrombotic phenotype associated with this mutation (Lowe
et al, 2000). A high thrombotic risk for the combination of
hormone use and factor V Leiden was analogous to the
synergistic effect we reported previously for oral contra-
ceptive use and factor V Leiden (Vandenbroucke et al,
1994). Furthermore, the new data suggest that the associ-
ation of the APC-resistant phenotype with increased risk of
venous thrombosis, as reported previously (Lowe et al,
2000), results from the pre-existing genetic mutation and
not from acquired APC resistance attributable to HRT or
venous thrombosis. A second analogy with thrombosis
resulting from oral contraceptive use was the association
with recent use (Bloemenkamp et al, 2000): for oral
contraceptives, we reported a higher risk during the first
year of use than for prolonged use, which was most
pronounced for women with inherited coagulation defects
(Bloemenkamp et al, 2000). In the original case–control
study, the risk was increased 3Æ1-fold during the first year of
hormone replacement and 2Æ1-fold during subsequent years
(both relative to non-users) (Daly et al, 1996). The prepon-
derance of first-year users among cases with a prothrom-
botic mutation (63%) also suggests a higher risk for these
women during the first year of HRT use, although the
number of women was too small to reach definite conclu-
sions.
The 15-fold increased risk of the combination of HRT
and factor V Leiden exceeds the expected joint risk based
on the separate effects, which would be a sixfold increased
risk (under an additive model). Because of the limited
number of women in the group with both risk factors,
however, the confidence interval around this estimate was
wide.
These results raise a safety issue, in particular the
question of how to minimize the use of HRT among women
with a high risk of thrombosis. This question is of
considerable importance, in particular because recently
the long-term arterial benefits of HRT have become doubt-
ful, with randomized trials failing to demonstrate a benefit
(Hulley et al, 1998). In making a decision to prescribe HRT,
risk minimization strategies may be considered that include
detailed history taking (personal and family history of
thrombosis) or screening for prothrombotic mutations. Such
policies might assist women and clinicians to make rational
and informed decisions. Even though a case–control study
only allows the calculation of relative risks, and not of
absolute risks, we can make some estimates about the effect
of selective prescription. The overall incidence of venous
thrombosis is one or two per 1000 per year and has a steep
age gradient (Rosendaal, 1997). Therefore, in absolute
terms, a relative risk of 4 associated with HRT has a much
larger impact on women’s health than the same relative risk
for oral contraceptives, as in women of reproductive age,
the incidence is about one per 10000, whereas in
post-menopausal women, it is over one per 1000 per year
and increases with more advanced age (Anderson et al,
1991; Nordstro¨m et al, 1992; Kniffin et al, 1994; Silverstein
et al, 1998; Lowe et al, 2000; Oger, 2000).
With a baseline incidence of one to four per 1000 per
year in women aged 45–79 years, screening for factor V
Leiden with a prevalence of 5%, and subsequent with-
holding of HRT in those tested positive, would prevent 5–25
thrombotic events annually per 10 000 women screened.
With 5 or 10 years of use, screening could well be
worthwhile. The effects of screening in preventing throm-
bosis are likely to be highest in older women. On the other
hand, it may prevent more thrombotic events and be more
cost-effective to withhold HRT in women with other risk
factors for venous thrombosis (such as gross obesity), or in
women with a family history of venous thrombosis.
In conclusion, the thrombotic risk of HRT may par-
ticularly affect women with prothrombotic mutations, spe-
cifically factor V Leiden. Given the high prevalence of this
mutation, efforts to minimize prescription of HRT to women
with an increased risk should be undertaken. The results
presented here are based on a relatively small study and
urgently need to be confirmed in a larger study, such as the
on-going trials of HRT.
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